Gri bio to present at the 2024 european respiratory congress

La jolla, ca, sept. 04, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 european respiratory congress (ers) being held september 7-11, 2024 in vienna, austria.
GRI Ratings Summary
GRI Quant Ranking